Showing 1 - 10 of 15
There were no innovations in chemotherapy for myeloma patients during the period 1977-1997, but there have been several important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma patients using both time-series U.S. data and...
Persistent link: https://www.econbiz.de/10010328754
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10010270528
Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled Why has longevity increased more in some states than in others?" One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent increases...
Persistent link: https://www.econbiz.de/10010272883
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995-2010. The estimates indicate that pharmaceutical innovation increased mean age at death by...
Persistent link: https://www.econbiz.de/10010480895
The nation's spending for prescription drugs has grown dramatically in recent years. Previous studies have shown that the replacement of older drugs by newer, more expensive, drugs is the single most important reason for this increase, but they did not measure how much of the difference between...
Persistent link: https://www.econbiz.de/10010315127
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% "G from 69.7 to 76.5 years "G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase,...
Persistent link: https://www.econbiz.de/10010315143
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010283600
Persistent link: https://www.econbiz.de/10008939210
Persistent link: https://www.econbiz.de/10002530448
Persistent link: https://www.econbiz.de/10002611006